Projecting burden of hypertension and its management in Turkey, 2015-2030
Autoři:
Ayda Aysun Yurekli aff001; Nazmi Bilir aff002; Muhammad Jami Husain aff003
Působiště autorů:
Visiting Senior Research Scientist at UIC Illinois, Chicago, Illinois, United States of America
aff001; Institute of Public Health, Hacettepe University, Ankara, Turkey
aff002; Global Noncommunicable Diseases Branch, Division of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
aff003
Vyšlo v časopise:
PLoS ONE 14(9)
Kategorie:
Research Article
doi:
https://doi.org/10.1371/journal.pone.0221556
Souhrn
Background
In Turkey, hypertension was responsible for 13% of total deaths in 2015. We apply existing research finding regarding the impact of a population-wide reduction in sodium consumption on the decrease of the hypertension prevalence rate among 15+ years population and the gender-age specific reduction in total death rates among 30+ years population, and compare hypertension burden, averted deaths, costs and benefits between two scenarios.
Methods
The first scenario (i.e. status quo) assumes constant hypertension prevalence rate and the death rates between 2015 and 2030. Based on the Framingham Heart Study and INTERSALT Study findings on the impact of salt-reduction strategies on hypertension prevalence rate, the second scenario (Scenario II) assumes a 17% reduction in the prevalence of hypertension in Turkey in 2030, from its 2015 prevalence level. We project hypertension attributable disability adjusted life years (DALYs) in 2030, monetize DALYs using GDP (and income) per capita, and compare the projected economic benefits of DALYs averted and the additional costs associated with the increases in hypertension treatment through antihypertensive medications and physician consultations.
Results
The estimated benefits of reducing the economic burden of hypertension deaths outweigh the cost of providing hypertension treatment. A decrease in hypertension prevalence by 17%, attributable to population-wide reduction in salt consumption, is projected to avert 24.3 thousand deaths in 2030. We projected that, compared to status quo, 392 thousand DALYs will be averted in Scenario II in 2030. The economic benefits of reduction in potential hypertension deaths are estimated to be 6.7 to 8.6 folds higher than the additional cost of hypertension treatment.
Conclusion
Population-wide hypertension prevention and management is a win-win situation for public health and the Turkish health care system as the economic benefits of reducing deaths and disabilities associated with hypertension outweigh the costs significantly.
Klíčová slova:
Medicine and health sciences – Vascular medicine – Blood pressure – Hypertension – Pharmacology – Drugs – Antihypertensives – Epidemiology – Medical risk factors – Biology and life sciences – Population biology – Population metrics – Death rates – People and places – Geographical locations – Asia – Turkey (country) – Europe – Population groupings – Age groups – Social sciences – Economics
Zdroje
1. World Health Organization. A global brief on hypertension: silent killer, global public health crisis: World Health Day 2013. World Health Organization; 2013.
2. IHME 2018. Global Health Data Exchange. Global Burden of Disease Study 2016 (GBD 2016) Data Resources. Institute for Health Metrics and Evaluation, University of Washington. http://ghdx.healthdata.org/gbd-2016
3. Mathers CD, Loncar D. Updated projections of global mortality and burden of disease, 2002–2030: data sources, methods and results. Geneva: World Health Organization. 2005 Oct.
4. Marks JS., McQueen DV. Chronic Disease. In: Critical Issues in Global Health, ed. Koop CE., Pearson CE., Schwarz MR. 2002. Pp. 117–26. San Francisco: Jossey-Bass.
5. National Institute of Health (NIH). The Seventh Report of the Joint National Committee (JNC7) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; US Department of Health and Human Services, NIH, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program. NIH publication; August 2004. https://www.ncbi.nlm.nih.gov/books/NBK9630/pdf/Bookshelf_NBK9630.pdf
6. Erdem Y, Akpolat T, Derici Ü, Şengül Ş, Ertürk Ş, Ulusoy Ş, Altun B, Arıcı M. Dietary sources of high sodium intake in Turkey: SALTURK II. Nutrients. 2017;9(9):933.
7. Erdem Y, Arici M, Altun B, Turgan C, Sindel S, Erbay B, Derici U, Karatan O, Hasanoglu E, Caglar S. The relationship between hypertension and salt intake in Turkish population: SALTURK study. Blood pressure. 2010 Oct 1;19(5):313–8. doi: 10.3109/08037051003802541 20698734
8. Trieu K, Neal B, Hawkes C, Dunford E, Campbell N, Rodriguez-Fernandez R, Legetic B, McLaren L, Barberio A, Webster J. Salt reduction initiatives around the world–a systematic review of progress towards the global target. PloS one. 2015 Jul 22;10(7):e0130247. doi: 10.1371/journal.pone.0130247 26201031
9. Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. The American journal of clinical nutrition. 1997 Feb 1;65(2):643S–51S.
10. Stamler R. Implications of the INTERSALT study. Hypertension. 1991 Jan;17 (1_supplement):I16.
11. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Archives of Internal Medicine. 1995 Apr 10;155(7):701–9. 7695458
12. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. Jama. 2002 Oct 16;288(15):1882–8. doi: 10.1001/jama.288.15.1882 12377087
13. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. New England journal of medicine. 2001 Jan 4;344(1):3–10. doi: 10.1056/NEJM200101043440101 11136953
14. World Bank. Health Nutrition and Population Database: Population estimates and projections. 2018. Avaialable from: http://databank.worldbank.org/data/reports.aspx?source=Health-Nutrition-and-Population-Statistics:-Population-estimates-and-projections
15. SALTURK II. 2012. http://turkhipertansiyon.org/tuz_280512.php & www.turkhipertansiyon.org/pdf/salt_160608.ppt
16. Global Adult Tobacco Survey (GATS) comparison fact sheet: Turkey 2008 and 2012. http://www.who.int/tobacco/surveillance/survey/gats/gats_turkey_2008v2012_comparison_fact_sheet.pdf
17. Republic of Turkey Ministry of Health. Global Adult Tobacco Survey Turkey 2012. Ministry of Health Publication No: 948. 2014. Ankara.
18. Dastan I, Erem A, Cetinkaya V. Awareness, treatment, control of hypertension, and associated factors: Results from a Turkish national study. Clinical and Experimental Hypertension. 2018 Jan 2;40(1):90–8. doi: 10.1080/10641963.2017.1334797 28686064
19. Republic of Turkey Ministry of Health. Chronic Diseases and Risk Factors Survey in Turkey. 2013. Ministry of Health Publication No: 909. Republic of Turkey Ministry of Health Turkish Public Health Institution, Chronic Diseases, Elderly Health, and Disabled Department.
20. Satman I, Yilmaz T, Sengül A, Salman S, Salman F, Uygur S, Bastar I, Tütüncü Y, Sargin M, Dinççag N, Karsidag K. Population-based study of diabetes and risk characteristics in Turkey: results of the turkish diabetes epidemiology study (TURDEP). Diabetes care. 2002 Sep 1;25(9):1551–6. doi: 10.2337/diacare.25.9.1551 12196426
21. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, Karsidag K, Genc S, Telci A, Canbaz B, Turker F. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. European journal of epidemiology. 2013 Feb 1;28(2):169–80. doi: 10.1007/s10654-013-9771-5 23407904
22. Altun B, Arici M, Nergizoglu G, Derici Ü, Karatan O, Turgan Ç, Sindel S, Erbay B, Hasanoglu E, Çaglar S. Prevalence, awareness, treatment and control of hypertension in Turkey (the PatenT study) in 2003. Journal of hypertension. 2005 Oct 1;23(10):1817–23. 16148604
23. PatenT I 2003: Turkish Society of Hypertension and Renal Diseases. http://turkhipertansiyon.org/prevelans_calismasi.php
24. Paten T II. 2012. Turkish Society of Hypertension and Renal Diseases. http://turkhipertansiyon.org/prevelans_calismasi_2.php
25. Arici M, Turgan C, Altun B, Sindel S, Erbay B, Derici U, Karatan O, Erdem Y, Hasanoglu E, Caglar S. Hypertension incidence in Turkey (HinT): a population-based study. Journal of hypertension. 2010 Feb 1;28(2):240–4. doi: 10.1097/HJH.0b013e328332c36b 19809361
26. TUIK 2015. Saglik istatistikleri yilligi: Annual health statistics. http://ekutuphane.sagem.gov.tr/kitaplar/saglik_istatistikleri_yilligi_2015.pdf
27. Nugent R, Brower E, Cravioto A, Koehlmoos T. A cost-benefit analysis of a National Hypertension Treatment Program in Bangladesh. Preventive medicine. 2017 Dec 1;105:S56–61.
28. Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, Lawes CM, Evans DB. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. The Lancet. 2003 Mar 1;361(9359):717–25.
29. Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. The Lancet. 2007 Dec 15;370(9604):2044–53.
30. Murray CJL, Lopez AD, eds.. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Global Burden of Disease and Injury Series, Vol. 1. Cambridge: Harvard University Press; 1996.
31. Murray CJL., Lopez A. Global Health Statistics. Cambridge, Harvard University Press (Global Burden of Disease and Injury Series, Vol. 2). 1996.
32. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. The lancet. 1997 May 17;349(9063):1436–42.
33. Norman R, Bradshaw D, Schneider M, Pieterse D, Groenewald P. Revised burden of disease estimates for the comparative risk factor assessment, South Africa 2000. Cape Town: Medical Research Council. 2006.
34. World Health Organization. The global burden of disease: 2004 update. Geneva. 2008. https://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf?ua=1
35. World Bank, World Development Report 1993; investing in health. Oxford. Oxford University Press, 1993.
36. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors. Priorities in health. The World Bank; 2006 Apr 2.
37. World Health Organization (WHO). Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva, Switzerland. 2001.
38. Robinson LA, Hammitt JK, Chang AY, Resch S. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy and Planning. 2016 Jul 24;32(1):141–5. doi: 10.1093/heapol/czw096 27452949
39. Augustovski F, Colantonio LD, Galante J, Bardach A, Caporale JE, Zárate V, et al. Measuring the benefits of healthcare: DALYs and QALYs–Does the choice of measure matter? A case study of two preventive interventions. International journal of health policy and management. 2018 Feb;7(2):120.
40. Edwards C. Social Cost-Benefit Analysis–the available evidence on drinking water. Valuing Water–Valuing Well-being: A Guide to Understanding the Costs and Benefits of Water Interventions. 2008.
41. TUIK Causes of Death Statistics 2018. http://www.tuik.gov.tr/PreHaberBultenleri.do?id=24572
42. TUIK Health Statistics 2016. https://biruni.tuik.gov.tr/demografiapp/olum.zul
43. Pektas MB, Aldemir M, Pektas A, Akci O, Dogan I. Would Anti-Hypertensive Treatment be a Risk Factor for National Health Budget of Turkey in 2023?. Medicine Science.;4(4):2813–24.
44. Sadler K, Nicholson S, Steer T, Gill V, Bates B, Tipping S, Cox L, Lennox A, Prentice A. Assessment of dietary sodium levels among adults (aged 19–64) in England, 2011. London: Department of Health. 2012.
45. He FJ, Pombo-Rodrigues S, MacGregor GA. Salt reduction in England from 2003 to 2011: its relationship to blood pressure, stroke and ischaemic heart disease mortality. BMJ open. 2014 Apr 1;4(4):e004549. doi: 10.1136/bmjopen-2013-004549 24732242
46. Karppanen H, Mervaala E. Sodium intake and hypertension. Progress in cardiovascular diseases. 2006 Sep 1;49(2):59–75. doi: 10.1016/j.pcad.2006.07.001 17046432
47. Laatikainen T, Pietinen P, Valsta L, Sundvall J, Reinivuo H, Tuomilehto J. Sodium in the Finnish diet: 20-year trends in urinary sodium excretion among the adult population. European journal of clinical nutrition. 2006 Aug;60(8):965. doi: 10.1038/sj.ejcn.1602406 16482074
48. Pietinen P, Valsta LM, Hirvonen T, Sinkko H. Labelling the salt content in foods: a useful tool in reducing sodium intake in Finland. Public health nutrition. 2008 Apr;11(4):335–40. doi: 10.1017/S1368980007000249 17605838
49. Sasaki N. The salt factor in apoplexy and hypertension: epidemiology studies in Japan. Prophylactic approach to hypertensive diseases. 1979:467–74.
50. He FJ, MacGregor GA. Salt and sugar: their effects on blood pressure. Pflügers Archiv-European Journal of Physiology. 2015 Mar 1;467(3):577–86. doi: 10.1007/s00424-014-1677-x 25547872
Článek vyšel v časopise
PLOS One
2019 Číslo 9
- S diagnostikou Parkinsonovy nemoci může nově pomoci AI nástroj pro hodnocení mrkacího reflexu
- Je libo čepici místo mozkového implantátu?
- Pomůže v budoucnu s triáží na pohotovostech umělá inteligence?
- AI může chirurgům poskytnout cenná data i zpětnou vazbu v reálném čase
- Nová metoda odlišení nádorové tkáně může zpřesnit resekci glioblastomů
Nejčtenější v tomto čísle
- Graviola (Annona muricata) attenuates behavioural alterations and testicular oxidative stress induced by streptozotocin in diabetic rats
- CH(II), a cerebroprotein hydrolysate, exhibits potential neuro-protective effect on Alzheimer’s disease
- Comparison between Aptima Assays (Hologic) and the Allplex STI Essential Assay (Seegene) for the diagnosis of Sexually transmitted infections
- Assessment of glucose-6-phosphate dehydrogenase activity using CareStart G6PD rapid diagnostic test and associated genetic variants in Plasmodium vivax malaria endemic setting in Mauritania
Zvyšte si kvalifikaci online z pohodlí domova
Všechny kurzy